Journal of the Formosan Medical Association (Sep 2022)

The effectiveness and safety of vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: A real practice observational study

  • Chia-Jung Kuo,
  • Puo-Hsien Le,
  • Wei-Chen Tai,
  • Keng-Liang Wu,
  • Hsu-Heng Yen,
  • Chih-Wei Yen,
  • Shui-Yi Tung,
  • Chen-Shuan Chung,
  • Ming-Yao Su,
  • Cheng-Tang Chiu

Journal volume & issue
Vol. 121, no. 9
pp. 1689 – 1695


Read online

Background: The use of biologic agents has become the cornerstone of therapy for moderate to severe IBD. Few studies have investigated the efficacy of vedolizumab (VDZ) induction for ulcerative colitis (UC) in Asian patients in a real practice setting. Aims: To evaluate the efficacy and safety of VDZ induction therapy for moderate to severe UC in Taiwan. Methods: This was a retrospective and observational study. Selected moderate to severe UC patients received VZD 300 mg i.v. at weeks 0, 2, and 6 as induction therapy. Mayo scores were calculated to evaluate the efficacy. Results: A total of 37 patients with UC who received VDZ and completed the induction therapy at Chang Gung Memorial Hospital (2017/10–2021/5) were included. The mean age was 46.5 year-old and the male to female ratio was 1:1 (19/18). 81.8% of the patients were biologic-naive. At weeks 8–10, a clinical response, clinical remission and endoscopic remission with VDZ induction therapy were achieved in 56.8% (21/37), 32.4% (12/37) and 58.3% (7/12) of the patients, respectively. 54.1% (20/37) were able to taper off at week 8. Overall, only 10.8% (4/37) of the patients were primary non-responders during induction therapy. No obvious VDZ-related severe adverse events were noted. Overall, 58.9% (11/19) of the patients relapsed after stopping VDZ, and the relapse rate after VDZ discontinuation was 42.1% (8/19) within first 6 months and 52.6% (10/19) within the first year. Conclusion: In real-world experience, induction therapy with VDZ showed promising clinical benefits and safety profile for patients with UC.